Qiagen N.V. (QGEN) News
Follow Qiagen N.V. (QGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 60 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
QIAGEN Reports Q3 Revenue Growth, Suspends 2026 Guidance Amid EQT Offer
QIAGEN reported Q3 revenue of $548 million, up 2.8% and above its previous outlook. Adjusted diluted EPS was $0.65 versus $0.61 a year earlier; GAAP EPS was $0.51 versus $0.60. The company suspended its 2026 guidance ami
EQUITY | Nov 09, 2026, 05:03 PM UTC
M
Qiagen Beats Q3 EPS by $0.02, Suspends 2026 Outlook
Qiagen reported Q3 earnings of $0.65 per share, excluding non-recurring items, $0.02 above the comparison cited in the headline. The company suspended its 2026 outlook due to a pending transaction with EQT Private Equity
EARNINGS | Nov 04, 2026, 09:26 PM UTC
M
QIAGEN Reports Q3 2026 Results, Sales Rise 3% to $548 Million
QIAGEN said third-quarter sales and adjusted diluted EPS were ahead of its outlook, in line with preliminary results. Sales rose 3% year over year to $548 million.
EQUITY | Nov 04, 2026, 09:09 PM UTC
M
Advent raises funds for new investment vehicles
Reuters reports that investment firm Advent has raised funds for new funds.
EQUITY | Oct 27, 2026, 10:00 AM UTC
M
EQT to Buy Qiagen for $12 Billion
EQT will acquire Qiagen for $12 billion, an offer described as barely above one rejected by shareholders in 2020.
MNA | Oct 22, 2026, 09:50 AM UTC
H
QIAGEN Agrees to EQT Takeover Offer Valuing Company at €10.8 Billion
Qiagen said it agreed to an all-cash takeover offer from EQT Private Equity at €46.50 per share. The deal values the company at approximately €10.8 billion, or $12.1 billion, including $1.1 billion of net debt.
MNA | Oct 22, 2026, 05:36 AM UTC
M
EQT-Led Coalition Reaches Deal to Take Qiagen Private at $12.1 Billion EV
A coalition led by Swedish private-equity firm EQT agreed to take Qiagen private at an enterprise value of around $12.1 billion, including $1.1 billion in net debt. Qiagen said its board unanimously determined that the t
MNA | Oct 21, 2026, 10:15 PM UTC
M
EQT Agrees to Buy Qiagen for EUR46.50 per Share
MNA | Oct 21, 2026, 09:53 PM UTC
M
EQT-Backed Bidco to Offer €46.50 per Share for QIAGEN
Crown NL Bidco, backed by EQT XI, ADIA and CPP Investments, will launch a voluntary cash offer for QIAGEN. The offer is subject to a 50% plus one acceptance minimum, EGM approvals and regulatory clearances; closing is ex
MNA | Oct 21, 2026, 09:53 PM UTC
M
Qiagen preliminarily reports 3Q adjusted EPS
EARNINGS | Oct 21, 2026, 09:46 PM UTC
M
Qiagen Reports Preliminary 3Q Net Sales of $548M
Qiagen reported preliminary third-quarter net sales of $548 million at both reported and constant exchange rates.
EARNINGS | Oct 21, 2026, 09:45 PM UTC
M
QIAGEN Concludes Business Combination Agreement With EQT Private Equity
QIAGEN also disclosed preliminary third-quarter 2026 results and suspended its full-year 2026 outlook.
EQUITY | Oct 21, 2026, 09:44 PM UTC
M
Qiagen Agrees EUR 10.8 Billion EQT Buyout, Suspends 2026 Outlook
MNA | Oct 21, 2026, 09:42 PM UTC
M
Deal Values Qiagen at About $12.1B in Enterprise Value
MNA | Oct 21, 2026, 09:40 PM UTC
M
EQT AB Agrees to Buy Qiagen
MNA | Oct 21, 2026, 09:39 PM UTC
M
EQT in Advanced Talks to Acquire Qiagen, Bloomberg Reports
Qiagen is in advanced talks to be acquired by Swedish buyout firm EQT, Bloomberg News reported, citing people familiar with the matter.
EQUITY | Oct 20, 2026, 06:04 PM UTC
M
EQT in Advanced Talks to Buy Testing Firm Qiagen
Bloomberg News reports EQT is in advanced talks to buy Qiagen.
MNA | Oct 20, 2026, 04:45 PM UTC
L
QIAGEN N.V. (QIA) Wins FDA Clearance, Completing U.S. QIAstat-Dx BSI Portfolio
QIAGEN received FDA clearance for its QIAstat-Dx BCID GN Plus AMR Panel, enabling U.S. labs to run both gram-negative and gram-positive/fungal bloodstream infection panels on QIAstat-Dx with ~1-hour results.Material Deta
REGULATION | Sep 28, 2026, 05:30 AM UTC
L
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Foo
REGULATION | Sep 28, 2026, 05:30 AM UTC
L
QIAGEN N.V. (QIA) Launches QIAmini For Small-Batch Automation
QIAGEN launched QIAmini, a compact system that automates DNA/RNA extraction for up to eight samples, targeting over 100,000 potential instrument placements worldwide. It reduced hands-on time by over 80% across evaluated
NEWS | Sep 24, 2026, 08:06 PM UTC
L
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alterna
NEWS | Sep 24, 2026, 08:05 PM UTC
L
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights
QIAGEN N.V. said the Dutch AFM disclosed a Sep 18, 2026 notification from BlackRock on holdings in Qiagen, totaling 11.42% capital interest and 12.83% voting rights, all indirect and including real and potential position
NEWS | Sep 23, 2026, 08:07 PM UTC
L
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights
QIAGEN N.V. reported that the Dutch AFM disclosed a notification by BlackRock, Inc. regarding its voting rights in QIAGEN dated Sep 18, 2026. QIAGEN relayed the notice and referred to the AFM register for details.Materia
NEWS | Sep 23, 2026, 08:07 PM UTC
L
QIAGEN N.V. (QIA) Notes AFM Voting Rights Notice
QIAGEN N.V. said the Dutch AFM disclosed a voting rights notification related to the company by Millennium International Management LP dated Sep 16, 2026.Material DetailsContext by AI AnalystThis is a late confirmation v
REGULATION | Sep 23, 2026, 08:07 PM UTC
L
QIAGEN N.V. (QIA) Notified of 2.99% Voting Rights by Millennium
AFM disclosed that Millennium International Management LP notified a 2.99% holding in QIAGEN N.V. as of Sep 16, 2026, including 1.66% real via ordinary shares and 1.32% potential via derivatives.Material DetailsContext b
EQUITY | Sep 23, 2026, 08:07 PM UTC
L
QIAGEN N.V. (QIA) Notes AFM Voting Rights Filing by Goldman Sachs
QIAGEN N.V. says the Dutch AFM disclosed a voting rights notification regarding the company, filed by Goldman Sachs Group Inc., dated 16 Sep 2026. Qiagen relays the notice from the AFM register and disclaims responsibili
NEWS | Sep 23, 2026, 08:06 PM UTC
L
QIAGEN N.V. (QIA) Discloses Goldman Sachs 3.41% Voting Rights
QIAGEN N.V. reported an AFM notification that Goldman Sachs Group holds 3.41% of voting rights and capital interest in QIAGEN as of Sep 16, 2026, via a mix of real and potential positions.Material DetailsContext by AI An
NEWS | Sep 23, 2026, 08:06 PM UTC
L
QIAGEN N.V. (QIA) Discloses Goldman Sachs 2.6% Voting Rights
QIAGEN N.V. said the Dutch AFM disclosed a Goldman Sachs Group Inc. notification showing 2.60% voting rights and capital interest in QIAGEN as of Sep 17, 2026, including real and potential positions via shares, options,
EQUITY | Sep 23, 2026, 08:06 PM UTC
L
QIAGEN N.V. (QIA) Notes AFM Disclosure on Goldman Sachs Voting Rights
QIAGEN said the Dutch AFM disclosed a notification by Goldman Sachs Group Inc. regarding voting rights in QIAGEN, dated Sep 17, 2026. Details are on the AFM register.Material DetailsContext by AI AnalystThis is a regulat
NEWS | Sep 23, 2026, 08:06 PM UTC
L
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V.by Investor RelationsRelease according to article 40 para. 1 WpHG (AFM) Venlo (pta/23.09.2026/22:05) - Release of Voting Rights Announcement The AFM (the Netherlands Authority For the Financial Markets) has in
NEWS | Sep 23, 2026, 08:05 PM UTC
L
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V.by Investor RelationsRelease according to article 40 para. 1 WpHGQIAGEN N.V.: Release according to Article 40, Section 1 of the WpHGVenlo (pta000/23.09.2026/22:05 UTC+2) - Release of Voting Rights Announcement
NEWS | Sep 23, 2026, 08:05 PM UTC
L
QGEN: Growth, AI-driven automation, and disciplined capital allocation drive strong margin performance
Leadership emphasized growth, margin expansion, and commercial excellence, with AI and automation initiatives underway to drive efficiency and new product launches ramping through 2027. Market dynamics remain challenging
NEWS | Sep 14, 2026, 06:47 PM UTC
L
QIAGEN N.V. voting rights release under WpHG Article 40
Qiagen N.V. said the AFM informed it on September 5, 2026 of a voting-rights notification related to the institution. The company made the release under article 40 para. 1 WpHG (AFM).
REGULATION | Sep 09, 2026, 08:05 PM UTC
L
UBS cuts Qiagen price target, keeps rating neutral
UBS cut its Qiagen price target to $47.00 per share from $52.00 while maintaining a neutral rating, according to TradingView News via Benzinga.
EQUITY | Sep 09, 2026, 06:24 PM UTC
L
Qiagen managers’ transactions notification filed under Article 19 MAR
QIAGEN N.V. posted a managers’ transactions announcement according to Article 19 MAR. The notification concerns Jonathan M. Pratt and includes his position and the reason for reporting.
EQUITY | Sep 08, 2026, 08:10 PM UTC
L
Qiagen managers’ transactions disclosed under Article 19 MAR
Qiagen N.V. Investor Relations issued a managers’ transactions announcement under Article 19 MAR, dated Venlo (08.09.2026).
EQUITY | Sep 08, 2026, 08:10 PM UTC
L
Qiagen voting rights release filed with AFM under WpHG Article 40
Qiagen N.V. said the AFM informed it regarding a release of voting rights announcement under Article 40, paragraph 1 of the WpHG. The notice is dated Venlo (04.09.2026).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
Qiagen voting rights release filed via AFM notice
Qiagen N.V. issued a voting rights announcement release under Article 40 Section 1 of the WpHG, following an AFM notification. Dated Venlo (02.09.2026).
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
QIAGEN notified of voting rights announcement under WpHG Article 40
QIAGEN N.V. said the AFM informed it on August 29, 2026 of a notification related to the institution, published as a voting rights release under WpHG Article 40.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
EQUITY | Aug 28, 2026, 09:23 PM UTC
L
QIAGEN N.V. files Article 40, Section 1 WpHG release
QIAGEN N.V. has issued a release under Article 40, Section 1 of the WpHG.
EQUITY | Aug 28, 2026, 08:05 PM UTC
L
Release according to Article 40, Section 1 of the WpHG
Release according to Article 40, Section 1 of the WpHG
EQUITY | Aug 28, 2026, 08:05 PM UTC
M
Jury awards $4.8M damages over Evercode sales
Jury awarded $4.8M in damages for sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026.
EQUITY | Aug 28, 2026, 06:41 PM UTC
M
10x Genomics jury finds Qiagen unit Parse Biosciences infringed
U.S. jury found a Qiagen unit infringed patents held by Parse Biosciences, per TradingView News.
EQUITY | Aug 28, 2026, 06:40 PM UTC
M
10x Genomics wins patent verdict against Parse Biosciences
10x Genomics won a patent infringement verdict against Parse Biosciences.
EQUITY | Aug 28, 2026, 06:39 PM UTC
L
TXG QGEN - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
TXG QGEN - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
EQUITY | Aug 28, 2026, 06:39 PM UTC
L
QGEN launches QIAsymphony Connect for automated clinical nucleic acid extraction
QGEN launched QIAsymphony Connect for automated clinical nucleic acid extraction.
EQUITY | Aug 27, 2026, 08:05 PM UTC
L
QGEN faces renewed M&A speculation
TradeXchange Newsdesk circulates M&A talk around QGEN, citing small-market circulations, without supplying deal terms or confirmation.
MNA | Aug 25, 2026, 06:54 PM UTC
L
QIAGEN appoints Jonathan M. Pratt CEO, reaffirms Q3 and FY26 guidance
QIAGEN N.V. appointed Jonathan M. Pratt chief executive officer effective September 1, 2026, succeeding Thierry Bernard, and reaffirmed its outlook for the third quarter and full-year 2026.
EQUITY | Aug 24, 2026, 01:51 PM UTC
L
Qiagen appoints Jonathan M. Pratt as chief executive officer
Qiagen N.V. appoints Jonathan M. Pratt as chief executive officer, effective September 1, 2026.
EQUITY | Aug 24, 2026, 01:48 PM UTC
H
Qiagen names Jonathan M. Pratt CEO effective September 1, 2026
Qiagen N.V. says Jonathan M. Pratt will become CEO effective September 1, 2026, and will be proposed as a managing director at an extraordinary general meeting planned for Q4 2026.
EQUITY | Aug 24, 2026, 01:46 PM UTC
L
Qiagen FY2026 Adj EPS expected to be more than $2.43 vs $2.42 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.139B Est
Qiagen (NYSE: QGEN ) FY2026 expected to be more than $2.43 vs $2.42 Est. affirms FY2026 sales outlook from $2.111 billion-$2.132 billion to $2.111 billion-$2.132 billion vs $2.139 billion estimate.
EARNINGS | Aug 05, 2026, 08:20 PM UTC
L
QGEN BMXXY New GeneXpert hints more competition pain for multiplex peers @ Exane
QGEN BMXXY New GeneXpert hints more competition pain for multiplex peers @ Exane
EQUITY | Jul 22, 2026, 01:43 PM UTC
L
QGEN qiagen highlights Molecular testing solutions supporting response to growing U.S. cyclospora outbreak
QGEN qiagen highlights Molecular testing solutions supporting response to growing U.S. cyclospora outbreak
EQUITY | Jul 15, 2026, 08:07 PM UTC
L
moves among today's downgrades IBM -23.4%, OI -6.9%, CRCL -4.1%, SLVM -3.7%, ARM -3.4%, IP -2.6%, PGR -2.3%, GEF -2.0%, TCBK -1.1%, PTRN -1.
moves among today's downgrades IBM -23.4%, OI -6.9%, CRCL -4.1%, SLVM -3.7%, ARM -3.4%, IP -2.6%, PGR -2.3%, GEF -2.0%, TCBK -1.1%, PTRN -1.0%, AAPL -1.0%, QGEN -0.9%, EQR -0.5%, AVB -0.5%, ELS -0.5%, TMHC +0.1%, EH +0.1
EQUITY | Jul 14, 2026, 01:52 PM UTC
L
QGEN downgraded form Buy to Hold W/ $45.50 PT (from $59) @ Berenberg
QGEN downgraded form Buy to Hold W/ $45.50 PT (from $59) @ Berenberg
EQUITY | Jul 14, 2026, 11:59 AM UTC
H
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Qiagen NV (NYSE: QGEN ) is drawing renewed investor attention after reports that several private equity firms are evaluating a potential takeover of the molecular diagnostics company. The stock surged 10.5% in the previo
MACRO | Jul 10, 2026, 01:26 PM UTC
M
Citi, MS, JPM Upgrade AHR, CDW, IBM
Citi, Morgan Stanley, JPMorgan, and others upgrade AHR, CDW, IBM, QGEN, SNPS, and TGT
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
IBM, QGEN, SNPS Upgraded
IBM, QGEN, and SNPS have been upgraded to OVERWEIGHT by JPM, MS, and Piper respectively
EQUITY | Jun 23, 2026, 09:40 AM UTC